People: Celsion Corp (CLSN.PH)

CLSN.PH on Philadelphia Stock Exchange

0.93USD
21 May 2013
Price Change (% chg)

$-0.03 (-2.86%)
Prev Close
$0.96
Open
$0.92
Day's High
$0.93
Day's Low
$0.92
Volume
3,800
Avg. Vol
--
52-wk High
--
52-wk Low
--

Search Stocks

Summary

Name Age Since Current Position

Max Link

 72 2001 Independent Chairman of the Board

Michael Tardugno

 61 2007 President, Chief Executive Officer, Director

Gregory Weaver

 56 2011 Chief Financial Officer, Senior Vice President

Jeffrey Church

 55 2011 Senior Vice President - Corporate Strategy and Investor Relations

Nicholas Borys

 53 2007 Vice President, Chief Medical Officer

Pok Yu Chow

 59 2007 Independent Director

Frederick Fritz

 61 2011 Independent Director

Robert Hooper

 65 2010 Independent Director

Alberto Martinez

 62 2010 Independent Director
» Insider Trading

Biographies

Name Description

Max Link

 Dr. Max E. Link, Ph.D., is Independent Chairman of the Board of Celsion Corporation since October 9, 2001. Dr. Link currently serves on the board of directors of a number of pharmaceutical and biotechnology companies. From 1993 to 1994, Dr. Link served as Chief Executive Officer of Corange, Ltd., a life science company that was subsequently acquired by Hoffman-LaRoche. From 1971 to 1993, Dr. Link served in numerous positions with Sandoz Pharma AG, culminating in his appointment as Chairman of their Board of Directors in 1992. From 2001 to 2003, Dr. Link served as Chairman and Chief Executive Officer of Centerpulse Ltd. Dr. Link currently serves on the Boards of Directors of Alexion Pharmaceuticals, Inc., Discovery Laboratories, Inc. and Cytrx Corporation. Dr. Link holds a Ph.D. in Economics from the University of St. Gallen (Switzerland). He has been a board member of the company since 1997.

Michael Tardugno

 Mr. Michael H. Tardugno is President, Chief Executive Officer, Director of Celsion Corporation. Mr. Tardugno was appointed President and Chief Executive Officer of the Company on January 3, 2007 and was elected to the Board of Directors on January 22, 2007. Prior to joining the Company and for the period from February 2005 to December 2006, Mr. Tardugno served as Senior Vice President and General Manager of Mylan Technologies, Inc., a subsidiary of Mylan Laboratories. From 1998 to 2005, Mr. Tardugno was Executive Vice President of Songbird Hearing, Inc. From 1996 to 1998, he was Senior Vice President of Technical Operations for a division of Bristol-Myers Squibb, and from 1977 to 1995, he held increasingly senior executive positions with Bausch & Lomb and Abbott Laboratories. Mr. Tardugno holds a B.S. degree in Biology from St. Bonaventure University and completed the Harvard Business School, Program for Management Development.

Gregory Weaver

 Mr. Gregory L. Weaver is Chief Financial Officer, Senior Vice President of Celsion Corporation since July 8, 2011. Mr. Weaver had been a director of the Company since June 2005. Mr. Weaver served as Poniard Pharmaceuticals’ Chief Financial Officer and Senior Vice President from August 2009 to August 2010. Prior to joining Poniard, a public oncology drug development company, Mr. Weaver served as Chief Financial Officer of Talyst, Inc., a privately-held pharmacy information product company, from 2007 to 2008. Prior to that, he served as Senior Vice President and Chief Financial Officer of Sirna Therapeutics, a public RNAI therapeutics company until the sale of the company to Merck, Inc. in 2006. From 2002 to 2005, Mr. Weaver was Chief Financial Officer of Nastech Pharmaceuticals, a public drug delivery company. From 1999 to 2002, Mr. Weaver was Chief Financial Officer of Ilex Oncology Inc., a public cancer drug development company, and from 1996 to 1998, he was Chief Financial Officer of Prism Technologies, a privately-held medical device manufacturer. In addition, Mr. Weaver held increasingly senior positions with Fidelity Capital in Boston and Arthur Andersen LLP. Mr. Weaver has also served as a Director and Chairman of the Audit Committee of SCOLR Pharmaceuticals, a public drug delivery company from 2007 to 2009. Mr. Weaver is a certified public accountant and received his MBA from Boston College and his B.S. in accounting from Trinity University.

Jeffrey Church

 Mr. Jeffrey W. Church is Senior Vice President - Corporate Strategy and Investor Relations of Celsion Corporation since July 8, 2011. Mr. Church joined Celsion in July 2010 as Vice President, Chief Financial Officer and Corporate Secretary. Immediately prior to joining Celsion, Mr. Church served as Chief Financial Officer and Corporate Secretary of Alba Therapeutics Corporation, a privately held life science company from 2007 until 2010. From 2006 until 2007, he served as Vice President, CFO and Corporate Secretary for Novavax, Inc., a publicly traded vaccine development company. From 1998 until 2006, he served as Vice President, CFO and Corporate Secretary for GenVec, Inc., a publicly traded life science and biotechnology company. Prior to that, he held senior financial positions at BioSpherics Corporation and Meridian Medical Technologies, both publicly traded companies. He started his career with Price Waterhouse from 1979 until 1986. Mr. Church holds a B.S. degree in accounting from the University of Maryland and is a Certified Public Accountant.

Nicholas Borys

 Dr. Nicholas Borys, M.D., is Vice President, Chief Medical Officer of Celsion Corporation since October 1, 2007. In this position, Dr. Borys manages the clinical development and regulatory programs for Celsion. Dr. Borys has accumulated experience in all phases of pharmaceutical development with a focus in oncology. Immediately prior to joining Celsion, Dr. Borys served as Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc., a molecular imaging and nuclear oncology pharmaceutical start-up company, from 2004 until 2007. From 2002 until 2004 he served as the Vice President and Chief Medical Officer of Taiho Pharma USA, a Japanese start-up oncology therapeutics company. Prior to that he held increasingly senior positions at Cytogen Corporation, Anthra Pharmaceuticals, Inc., Amersham Healthcare, Inc. and Hoffmann La-Roche Inc. Dr. Borys obtained his premedical degree from Rutgers University and holds an M.D. Degree from American University of the Caribbean.

Pok Yu Chow

 Dr. Pok Yu Chow, Ph.D., is Independent Director of Celsion Corporation since March 14, 2007. Dr. Chow has served as the Chief Executive Officer of Harmony Asset Limited since 1996, a publicly listed investment company specializing in China and Hong Kong. Dr. Chow has served as Executive Director of Kaisun Energy Group Ltd. since 2008 and currently serves as an independent director of Medifocus Inc. From 1990 to 1998, Dr. Chow was the Chief Executive Officer of Allied Group of Companies based in Hong Kong. Prior to this, Dr. Chow held a senior position with Brunswick Corporation and Outboard Marine Corporation and was responsible for all business activities in South East Asia and China. Dr. Chow’s qualifications also include a number of Bachelors, Masters and Doctoral degrees. Among them include a MSc from London Business School, a PhD in the Transfer of Technology from the University of South Australia, a DBA in Internet Research from Southern Cross University, and an Engineering Doctorate in the Commercialization of Radical Innovation and MPhil in the Development of Herbal TNF Antagonist for the Treatment of Rheumatoid Arthritis from City University of Hong Kong.

Frederick Fritz

 Mr. Frederick J. Fritz has been appointed as Independent Director of Celsion Corporation since July 8, 2011. Mr. Fritz is currently the CEO & Founder of NeuroDx, a development stage diagnostic device company focused on the neurosurgery market. Mr. Fritz joined NeuroDx from Valeo Medical, a biotech company he founded in 2003 to develop the world's first non-invasive diagnostic test for endometriosis. Prior to that, Mr. Fritz was President and CEO of Songbird Hearing, a medical device spin out of Sarnoff Corp. He is a University of Illinois engineer (summa cum laude) and a Harvard MBA. Mr. Fritz began his career in marketing management and new product development. He joined Schering Plough's Wesley Jessen in 1985 as VP Marketing and Sales in 1986. He was promoted to general manager of Schering's Over the Counter pharmaceutical business in 1988 and of the podiatric products business in 1990. He was President of Coleman North America from 1995-1997.

Robert Hooper

 Mr. Robert W. Hooper is Independent Director of Celsion Corporation since July 29, 2010. He is currently President of Crows Nest Ventures, Inc. a privately held company, and provides advisory and consulting services to the healthcare industry. From 1997 to 2001, Mr. Hooper served as President North America for IMS Health, a publicly traded healthcare information and market research company. From 1993 to 1997, he served as President of Abbott Laboratories Canada. From 1989 to 1993, he served as Managing Director, Australia/Asia for Abbott Laboratories. Prior to that, he held increasingly senior positions at E.R. Squibb and Sterling Winthrop Labs. Mr. Hooper holds a B.A degree in Biology from Wilkes University.

Alberto Martinez

 Dr. Alberto R. Martinez, M.D., is Independent Director of Celsion Corporation since December 6, 2010. He is currently a consultant to the healthcare industry. From 2007 to 2008, Dr. Martinez served as the President and Chief Operating Officer of Talecris Biotherapeutics, Inc., a publicly traded life science company. Prior to that, Dr. Martinez served as Talecris’ President and Chief Executive Officer from October 2005 until June 2007. Prior to that, he held increasingly senior positions as Executive Vice President of Worldwide Commercial Operations at ZLB Behring (subsequently renamed CSL Behring). Prior to ZLB Behring, Dr. Martinez served in various international positions at Sandoz Pharmaceutical (today Novartis) in Brazil, Switzerland, Spain and the U.S. for eighteen years. Dr. Martinez completed his undergraduate and graduate studies at the University of Sao Paulo and received his medical degree from the University of Sao Paulo in 1973. After completing his residency in Pediatrics in 1975, he studied Business and Marketing Administration at the Fundacao Getulio Vargas in Sao Paulo, Brazil.

Basic Compensation

Name Fiscal Year Total

Max Link

 --

Michael Tardugno

 875,216

Gregory Weaver

 581,293

Jeffrey Church

 454,701

Nicholas Borys

 510,776

Pok Yu Chow

 --

Frederick Fritz

 --

Robert Hooper

 --

Alberto Martinez

 --
As Of 30 Dec 2011

Insider Trading

Name Shares Traded Price

MARTINEZ ALBERTO R JR

 5,000 $0.96

MARTINEZ ALBERTO R JR

 5,000 $0.92

FRITZ FREDERICK J

 20,000 $1.06

MARTINEZ ALBERTO R JR

 3,750 $1.06

WEAVER GREGORY L

 37,272 $1.06

WEAVER GREGORY L

 8,636 $2.77

LINK MAX E

 14,000 $7.60

TARDUGNO MICHAEL H

 17,271 $2.77

MARTINEZ ALBERTO R JR

 34,583 $3.25

HOOPER ROBERT W

 11,600 $5.20

MARTINEZ ALBERTO R JR

 2,500 $2.36

MARTINEZ ALBERTO R JR

 34,542 $2.77

LINK MAX E

 17,083 $3.25

LINK MAX E

 18,735 $4.22

LINK MAX E

 35,000 $2.72

LINK MAX E

 34,542 $2.77

TARDUGNO MICHAEL H

 1,900 $5.04

CHURCH JEFFREY W

 2,000 $4.93

TARDUGNO MICHAEL H

 3,100 $5.03

HOOPER ROBERT W

 3,800 $4.96

HOOPER ROBERT W

 1,060 $4.92

HOOPER ROBERT W

 100 $4.94

HOOPER ROBERT W

 1,549 $4.97

HOOPER ROBERT W

 3,491 $4.95

HOOPER ROBERT W

 2,500 $4.65
» Full list on Insider Trading
Search Stocks